|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Azathioprine or 6-mercaptopurine for inducing remission of Crohn,s disease显示文摘 | Sandbom W Sutherland L Pearson D | 2000 | Co-chrane Database Syst Rev2000，，00： | 1 |
| 2 | A review of immune modifier therapy for in- flammatory bowel disease: azathioprine, 6-mercaptopurine, eyclosporine, and methotrexate 显示文摘 | Sandbom W J | 1996 | Am J Gastroenterol1996，91，3： | 1 |
| 3 | To- facitinib, an oral janus kinase inhibitor, in- active ulcerative colitis显示文摘 | Sandbom W J Ghosh S Panes J | 2012 | N Engl J Med2012，367，7： | 1 |
| 4 | Human anti-tumor necrosis factor monoclonal antibody (adalimumab)in Crohn's disease显示文摘 | Hanauer S B Sandbom W J Rutgeerts P | 2006 | Gastroenterology2006，130，2： | 1 |
| 5 | Crohns disease in Olmsted County, Minnesota, 1940 - 1993 : Incidence, prevalence, and survival 显示文摘 | Loftus E V Silverstein M D Sandbom W J | 1998 | Gastroenterology1998，114，6： | 1 |
| 6 | Ulcerative cotitis in Olmsted Country, Minnesota, 1940-1993 ; incidence, prevalence,and survival显示文摘 | Loftus Jr EV Silverstein MD Sandbom W J | 2000 | Gut2000，46，3： | 1 |
| 7 | Ulcerative colitis in Olmsted County, Minnesota, 1940 - 1993 : incidence, prevalence, and survival显示文摘 | Loftus E V Jr Silverstein M D Sandbom W J | 2000 | Gut2000，46，3： | 1 |
| 8 | Infliximab for induction and maintenance therapy for ulcerative colitis显示文摘 | Rutgeerts P Sandbom W J Feagan B G | 2005 | N Engl J Med2005，353，23： | 1 |
| 9 | Azathioprine or 6- mercaptopurine for inducing remission of Crohn's disease显示文摘 | Sandbom W Sutherland L Pearson D | 2000 | Co- chrane Database Syst Rev2000，，00： | 1 |
| 10 | A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ul- cerative colitis 显示文摘 | D' Haens G Sandbom W J Feagan B G | 2007 | Gastroenterology2007，132，2： | 1 |
| 11 | Long-term inf liximab maintenance therapy for ulcerative colitis:the ACT-1 and-2 extension studies显示文摘 | Reinisch W Sandbom WJ Rutgeerts P | 2012 | Inflamm Bowel Dis2012，18，： | 1 |
| 12 | Repifermin(keratinocyte growth factor-2)for the treatment of active ulcerative colitis:a randomized double-blind,placebo-controlled,dose-escalation trial显示文摘 | Sandbom W J Sands B E Wolf D C | 2003 | Aliment Pharmacoi Ther2003，17，11： | 1 |
| 13 | Management of Crohn' s disease in adults显示文摘 | LICHTENSTEIN G R HANAUER S B SANDBOM W J | 2009 | Am J Gastroenterol2009，104，： | 1 |
| 14 | Taking a closer look at IBD显示文摘 | Egan LJ Sandbom W | 2014 | Gut2014，63，2： | 1 |
| 15 | H u m a n anti-tumornecrosis factor monoclonal antibody ( adalimumab) in Crohn’sdisease ; the CLASSIC-I trial 显示文摘 | Hanauer S B Sandbom W J Rutgeerts P | 2006 | Gastroenterology - 20062006，591，： | 1 |
| 16 | Infliximab for induction and maintenance therapy for ulcerative colitis显示文摘 | Rutgeerts P Sandbom W J Feagan BG | 2005 | N Engl J Med2005，353，23： | 1 |
| 17 | Management of Crohn's disease in adults显示文摘 | Lichtenstein GR Hanauer SB Sandbom W J | 2009 | Am J Gastroenterol2009，104，2： | 1 |
| 18 | Ustekinumab induction and maintenance therapy in refractory Crohn disease显示文摘 | Sandbom W J Gasink C Gao LL | 2012 | N Engl J Med2012，16，： | 1 |
| 19 | Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ul- cerative colitis显示文摘 | Sandbom WJ van Assche G Reinisch W | 2012 | Gastroenterology2012，142，2： | 1 |
| 20 | A review ofactivity indices and efficacy end points for clinical trialsof medical therapy in adults with ulcerative colitis显示文摘 | D'Haens G Sandbom WJ Feagan BG W al | 2007 | Gas-troenterology2007，132，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员